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ABSTRACT
Glidewell, Markie, Pharm.D., May 2017

Pharmacy

University of Montana Students and the Gardasil® Vaccine
Faculty Mentor: Donna Beall
Gardasil® is a vaccine for human papilloma virus (HPV), a sexually transmitted virus that can
cause genital warts, cervical cancer, and other diseases. Males and females ages 9-26 are
recommended to receive the Gardasil® vaccination. Most students attending the University of
Montana (UM) are within the recommended age range for Gardasil® vaccination and would
benefit from receiving it if they have not yet done so. Gardasil® is available at the Health
Services Pharmacy on the UM campus and is often covered by insurance plans with no patient
copay. In the fall semester of 2016, surveys were given to patients at the Health Services
Pharmacy that inquired about the student’s Gardasil® vaccination status, barriers to vaccination
they may encounter, their knowledge of HPV, and the student’s opinion of the Gardasil®
vaccine. The results of the survey highlight a low vaccination rate in UM students, particularly in
male students. Respondents were unaware of both the vaccine and its availability at the Health
Services Pharmacy. In addition, a difference in knowledge about HPV was seen between
vaccinated and unvaccinated individuals, with more vaccinated respondents correctly answering
questions regarding Gardasil® and HPV. The results of this study suggest that a Gardasil®
educational campaign should increase HPV awareness and vaccination rates in the student
population at UM.

2

University of Montana Students and the Gardasil® Vaccine

Introduction
Gardasil® is a vaccination that protects against human papilloma virus (HPV), which can
cause seven different types of cancers, in addition to genital warts and precancerous lesions.
HPV is the most common sexually transmitted disease, with over 14 million new infections
occurring each year in the US, half of which occur in people ages 15-24 years old.1 The majority
of students that attend the University of Montana are within the recommended age range for
Gardasil® vaccination. Gardasil® is available at the Health Service Pharmacy, a pharmacy
located on the UM campus that is exclusively available to UM students.
The purpose of this study is to assess the Gardasil® vaccination status of students at the
University of Montana as well as their knowledge and opinion of the vaccine.

Background
The Gardasil® vaccine was introduced in the US in 2006. It provided protection against
HPV types 6, 11, 16, and 18. HPV is transmitted through sexual contact and can cause genital
warts, precancerous lesions, and cancers such as cervical, vulvar, vaginal, oropharyngeal, penile,
anal, and rectal cancers.2 While some strains of HPV are mild and resolve spontaneously,
approximately 13 strains are linked to the development of cancer.3 Gardasil 9®, which recently
replaced Gardasil®, was approved in 2014 and provides coverage against five additional strains
of HPV. Vaccination with Gardasil 9® is recommended for both males and females ages 9
through age 26. Limitations of Gardasil® include the continued necessity of regular cervical and
anal cancer screening, the inability to protect against HPV strains that a person has been exposed
to prior to the vaccine, and the inability to treat active precancerous lesions and cancers.4 Even
though the ideal time of vaccination is before the individual becomes sexually active, vaccination
of sexually active individuals is still recommended because the individual may have not been
exposed to every strain of HPV covered by the vaccine.
A recent CDC analysis found that between 2008 and 2012, the rates of HPV-associated
cancer incidence increased compared to 2004 to 2008, from 10.8 per 100,000 to 11.7 per
100,000. Between 2008-2012, approximately 38,793 HPV-associated cancers were diagnosed
annually in the United States, with approximately 79% of those cases being attributed to HPV.
3

Of those cases attributed to HPV, 93% are due to the HPV strains that are preventable with the
Gardasil 9® vaccine.3
Universal vaccination with Gardasil 9® has the potential to decrease the incidence of
HPV-associated cancers by over two-thirds. Cervical cancer can theoretically be eradicated with
universal vaccination, which would also reduce the need for additional medical care and invasive
procedures that result from an abnormal cervical screening. Non-cervical HPV-associated
cancers, including oropharyngeal, penile, anal, and rectal cancers, do not have established
screening programs and the rates of these cancers will also dramatically decrease as a result of
the Gardasil® vaccination.5
While this vaccine holds great promise for decreasing the incidence of many cancers,
vaccination rates have remained low. In 2014, national HPV vaccine coverage was 60% for
adolescent girls and 42% for adolescent boys, leaving the unvaccinated adolescents at risk for
contracting an HPV infection that may otherwise be preventable.6

Methods
Optional anonymous surveys (see Appendix A) were given to patients at the Health
Services Pharmacy. If a patient chose to participate, they completed the survey and returned it to
a collection box and were offered additional Gardasil® educational materials (see appendix B).
The survey was offered to patients at the pharmacy from August 31 through November 24, 2016.
After the survey period, surveys were analyzed to compare vaccination rates, knowledge of
HPV, and opinion of the importance of vaccination.

Results
Eighty-six surveys were completed and submitted. Of the submitted surveys, 19 (22%)
respondents were male and 67 (78%) were female. The most common age range of respondents
was 18-22 years old (n=71, 83%), followed by ages 23-26 (n=11, 13%), and ages over 26 (n=4,
5%). Thirty-two respondents (37%) reported that they had received the Gardasil® vaccine, 26
respondents (30%) had not received the vaccine, and 28 respondents (33%) did not know if they
had received the vaccine. Eleven percent of males reported that they had received the vaccine,
and 45% of females reported vaccination.
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If you have not received the vaccine, what are your reasons for not getting it?
The most common reason for not receiving the vaccine was that respondents were not
aware of the vaccine. Thirty-eight of respondents did not answer this question, the majority of
whom reported that they had received the vaccine.

Table 1: Reasons for non-vaccination
Reason
Time
Cost
Against vaccines
Unaware of the vaccine
Safety concerns
Other
Did not answer question

Frequency (n)
12% (8)
3% (2)
3% (2)
31% (27)
6% (4)
7% (5)
44% (38)

If the cost of the Gardasil® vaccine prevents you from getting it, would you get it if it were
free?
Forty-one respondents (48%) answered that they would get the vaccine if it were
provided for free, 2 respondents (2%) would not get the vaccine if it were free, and 31
respondents (36%) answered ‘not applicable’, most likely because they had already received the
vaccine.
Did you know that the Gardasil® vaccine is available at the Health Services Pharmacy on
campus?
Twenty-one respondents (24%) knew that Gardasil® is available at the Health Services
Pharmacy while 60 respondents (70%) did not know of the vaccine’s availability. Five
respondents (6%) did not answer this question.
To the best of your knowledge, the Gardasil® vaccine is used to protect people from what
pathogen?
Most respondents selected the correct answer, human papilloma virus. The second most
common answer was pertussis. Of the respondents who received the vaccine, 31 (96%) selected
the correct answer, while only 17 (65%) of respondents who were unvaccinated answered this
question correctly.
5

Table 2: Pathogen Gardasil® protects against
Pathogen
Pertussis
Measles
Human Papilloma Virus
Typhoid
Multiple answers chosen
No response

Frequency (n)
7% (6)
3% (3)
76% (65)
2% (2)
1% (1)
10% (9)

To the best of your knowledge, what condition can Gardasil® help prevent people from
acquiring?
The correct answer, cervical cancer, was selected by most respondents. The second most
common answer was hepatitis. Of the respondents who received the vaccine, 26 (81%) answered
this question correctly, while only 9 (35%) respondents who were unvaccinated were correct.
Table 3: Condition Gardasil® protects against
Condition
Influenza
Cervical Cancer
Hepatitis
Meningitis
Multiple answers chosen
No response

Frequency (n)
7% (6)
51% (44)
20% (17)
6% (5)
7% (6)
9% (8)

In your opinion, how important is getting the Gardasil® vaccine?
While 40% of respondents thought that receiving the Gardasil® vaccine was ‘very
important’, 29% had no opinion on the value of Gardasil®. More respondents who had received
the vaccine believed the vaccine to be ‘very important’ compared to those who had not received
the vaccine (23 [71%] versus 3 [11%], respectively).
Table 4: Importance of Gardasil®
Opinion
No opinion
Not important
Somewhat important
Very important
No response

Frequency (n)
29% (25)
1% (1)
23% (20)
40% (34)
7% (6)
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Discussion
If vaccination data obtained from this study is correct and extrapolated to the UM student
population, vaccination rates of UM students are much lower than the national averages for both
men and women. This data also highlights a stark contrast in vaccination rates between men and
women at UM. A possible explanation for this occurrence is that Gardasil® was initially
recommended exclusively for females; it was not until 2016 that the American Cancer Society
updated its recommendations on HPV vaccination to include males.7
Lack of knowledge of HPV may be influencing low vaccination rates in this population,
which is supported by responses to the knowledge-based survey questions. More respondents
who were vaccinated answered the knowledge questions correctly compared to unvaccinated
respondents. This data shows that people who have received the vaccine may be more likely to
have knowledge of HPV and its associated cancers. Additionally, most respondents did not know
that Gardasil® is available on campus. These results support the implementation of a Gardasil®
education campaign on campus to increase awareness about HPV and vaccination. This would
likely increase vaccination rates and support of Gardasil® among the student population.
Possible limitations to these results include sample size, recall bias, and selection bias.
With over 13,000 undergraduate students enrolled at UM, 86 is a very small sample size and may
not give a true reflection of this population. Respondents may also not remember if they received
the vaccine if they were vaccinated as an adolescent. In addition, students utilizing the Health
Service Pharmacy may be more likely to be vaccinated due to their interest in accessing
healthcare.
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APPENDIX A
Gardasil® Survey

Student Gardasil® Survey 2016
What is your gender?
What is your age range?
Have you received the Gardasil® vaccine?
If you have not received the vaccine, what are
your reasons for not getting it?
(mark all that apply)
If the cost of the Gardasil® vaccine prevents you
from getting it, would you get it if it were free?
Did you know that the Gardasil® vaccine is
available at the Health Service Pharmacy on
campus?
To the best of your knowledge, the Gardasil®
vaccine is used to protect people from what
pathogen?
To the best of your knowledge, what condition can
Gardasil® help prevent people from acquiring?
In your opinion, how important is getting the
Gardasil® vaccine?

□ Male
□ 18-22
□ Yes
□ Time
□ Unaware of
…this vaccine
□ Yes

□ Female
□ 23-26
□ No
□ Cost of the
…vaccine
□ Safety concerns

□ Prefer not to answer
□ > 26
□ Don’t know
□ Don’t believe in
…vaccines
Other_______________

□ No

□ Not applicable

□ Yes

□ No

□ Pertussis

□ Measles

□ Influenza

□ Cervical
…cancer
□ Not
…important

□ No opinion

□ Human
…Papilloma…virus
□ Hepatitis

□ Typhoid

□ Somewhat
…important

□ Very
…important

□ Meningitis

The purpose of this anonymous survey is to assess student knowledge and values pertaining to the Gardasil ® vaccine.
Please place completed surveys in the drop box at the pharmacy

If you have any questions regarding the Gardasil® vaccine, please consult the pharmacist.
Thank you for participating in the survey!
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APPENDIX B
Gardasil® information provided to respondents
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